Bayer HealthCare and Onyx Pharmaceuticals have begun enrolling patients in a Phase III trial in order to evaluate Nexavar tablets in combination with oral chemotherapeutic capecitabine.

The trial was started based on positive results from a group-sponsored Phase II trial that evaluated the use of Nexavar in combination with capecitabine in patients with advanced breast cancer.

Bayer HealthCare vice-president of global clinical development oncology Dr Dimitris Voliotis said, “This Phase III trial is an important milestone in our development of Nexavar as it provides an opportunity to validate the promising Phase II results.”

In the Phase II trial, the patients given the combination had a 74% improvement in the time they lived without their cancer progressing compared to those who received chemotherapy alone.